ARVN Arvinas Forecast, Technical & Fundamental Analysis
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins... Show more
ARVN is expected to report earnings to fall 55.88% to -39 cents per share on July 30
Q2'26
Est.
$-0.40
Q1'26
Beat
by $0.03
Q4'25
Missed
by $0.59
Q3'25
Beat
by $0.23
Q2'25
Beat
by $0.10
The last earnings report on May 12 showed earnings per share of -89 cents, beating the estimate of -93 cents. With 711.05K shares outstanding, the current market capitalization sits at 499.07M.
A.I. Advisor
published General Information
General Information
a developer of therapies to degrade disease-causing proteins
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with XNCR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then XNCR could also see price increases.
ARVN sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ARVN moved below the 200-day moving average on May 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ARVN entered a downward trend on June 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where ARVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ARVN just turned positive on June 16, 2026. Looking at past instances where ARVN's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.290) is normal, around the industry mean (20.056). P/E Ratio (0.000) is within average values for comparable stocks, (35.869). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). ARVN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (5.949) is also within normal values, averaging (361.304).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
